News
Three cell & gene therapy groups - ISCT, ARM & ASGCT - jointly call for 10-year global ban on human germline gene editing, ...
Omada, the virtual chronic care provider, joins virtual physical therapy company Hinge Health in testing the public market’s ...
The Trump administration laid out for the first time how Part B drugs could be selected for Medicare drug price negotiations ...
A handful of generic and biosimilar manufacturers have said they feel prepared to ride out President Donald Trump’s potential ...
GSK said it is axing development of belrestotug and concluding its iTeos collaboration, which began with $625 million upfront ...
White House drug pricing plan faces skepticism as experts question feasibility of Trump's executive order to align US prices ...
Today on Post Hoc Live, Drew Armstrong is joined by Nick Shipley, the former top lobbyist for the biotech industry, ...
Galapagos is turning heads by reconsidering whether to do its planned spinoff, which was originally announced in January.
Bayer cuts 2,000 jobs in Q1 2025, reaching 11,000 total layoffs amid reorganization. CEO Bill Anderson reports strong pharma ...
Azafaros raises $146M Series B to advance nizubaglustat into Phase 3 trials for rare lysosomal storage disorders, with ...
President Donald Trump on Monday made a sweeping promise to bring down drug prices and stop pharma companies from taking ...
House tax bill includes PBM reforms, spread pricing restrictions & orphan drug negotiation changes, with Rep. Guthrie leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results